Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 1 2

Status

Withdrawn 2Unknown 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3Thoracic 1Sarcoma 1Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Multiple Myeloma 7Lymphoma, B-Cell 5Pancreatic Neoplasms 4Lymphoma, Non-Hodgkin 4Lymphoma, Large B-Cell, Diffuse 4Leukemia, Lymphocytic, Chronic, B-Cell 4Carcinoma, Hepatocellular 4Stomach Neoplasms 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Glioma 3Burkitt Lymphoma 3Recurrence 2Neoplasms 2Melanoma 2Lymphoma 2Lung Neoplasms 2Leukemia, Prolymphocytic, B-Cell 2Leukemia, Myeloid, Acute 2Leukemia, Myeloid 2Esophageal Neoplasms 2Colorectal Neoplasms 2Triple Negative Breast Neoplasms 1Solid Tumor 1Simpson-Golabi-Behmel syndrome 1Sarcoma, Synovial 1Prostatic Neoplasms 1Plasmacytoma 1Pelvic Neoplasms 1

Interventions

Temozolomide 26Radiotherapy 10Bevacizumab 10Carboplatin 6Irinotecan 5pembrolizumab 4Radiation 4Nivolumab 4IL13-PE38 4temsirolimus 3Surgical Procedures, Operative 3Magnetic Resonance Spectroscopy 3Immunotherapy, Adoptive 3Erlotinib Hydrochloride 3Aminolevulinic Acid 3trametinib 2olaparib 2lutetium Lu 177 dotatate 2fludarabine 2dabrafenib 2cemiplimab 2abemaciclib 2Vorinostat 2Transurethral Resection of Bladder 2Sirolimus 2Radiotherapy, Intensity-Modulated 2Radiosurgery 2Imatinib Mesylate 2Flucytosine 2Cyclophosphamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Glioma × Immunotherapy, Adoptive × Clear all
NCT02575261 2020-07-16

CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients

Fuda Cancer Hospital, Guangzhou

Phase 1/2 Withdrawn
CNS

Glioma

NCT03252171 2020-07-16

CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients

Fuda Cancer Hospital, Guangzhou

Phase 1/2 Withdrawn
CNS

Glioma

NCT03638206 2019-12-11

Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies

Shenzhen BinDeBio Ltd.

Phase 1/2 Unknown
73 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidOther hematologic neoplasmOther solid neoplasmPlasma cellSarcomaThoracic

Burkitt Lymphoma, Carcinoma, Renal Cell, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Leukemia, Myeloid, Lung Neoplasms, Lymphoma, Melanoma, Mesothelioma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Sarcoma, Synovial, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡